Oncology Learning NetworkMAJIC-PV Study Indicates Ruxolitinib Treatment Yields Superior Responses for Patients with Polycythemia Vera

Polycythemia vera often leads to thrombosis, hemorrhage, transformation to myelofibrosis, and early death.

A new study titled “MAJIC-PV”, led by Dr. Claire Harrison, reveals that the drug ruxolitinib could offer superior outcomes in patients suffering from polycythemia vera (PV), a rare form of blood cancer. This research brings to light the potential of ruxolitinib in extending event-free survival, overall survival, and molecular response among patients intolerant to hydroxycarbamide, a standard treatment for PV.

Key Points:

• The phase 2 MAJIC-PV trial results demonstrate that ruxolitinib outperforms the best available therapy in patients intolerant to hydroxycarbamide suffering from polycythemia vera (PV).
• Ruxolitinib treatment showed enhanced event-free survival, complete response, molecular response, and overall durable responses.
• The study suggests that molecular response (the reduction of JAK2 variant allele frequency by 50%) is tied to event-free survival, progression-free survival, and overall survival.

Additional Points:

• Patients treated with ruxolitinib had superior thrombosis-free survival and time to discontinuation of treatment.
• Controlling all parameters of the blood count, regardless of the therapy, was associated with event-free survival.
• Additional driver mutations, particularly SXR1 mutations, correlated with worse event-free survival and decreased likelihood of achieving a molecular response.
• No new safety concerns were associated with ruxolitinib, a fact important for practitioners considering the treatment for their patients.

Conclusion:

• The MAJIC-PV study affirms the effectiveness of ruxolitinib in managing PV, particularly for hydroxycarbamide-intolerant patients, with improved event-free and overall survival rates. The findings also underscore the importance of controlling blood count parameters and monitoring the JAK2 variant allele frequency as novel methods of managing disease progression.

Hematology/Oncology Latest Posts

• 18 Foods to Avoid to Reduce Cancer RiskOctober 21, 2024
• Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?October 21, 2024
• Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s LymphomaOctober 21, 2024
• Hematologic Cancer after Gene Therapy for Cerebral AdrenoleukodystrophyOctober 17, 2024